I. AMENDMENTS TO THE CLAIMS

This listing of claims shall replace all prior versions, and listings, of claims in the application.

Listing of Claims

1-37. (cancelled)

38. (previously presented): A method of effectively treating pain in humans comprising

orally administering to a human patient an oral dosage form comprising two analgesic compounds and/or pharmaceutically acceptable salts thereof consisting of

(i) meloxicam and/or at least one pharmaceutically acceptable salt thereof; and

(ii) oxycodone and/or at least one pharmaceutically acceptable salt thereof;

wherein the meloxicam and/or at least one pharmaceutically acceptable salt thereof is present in the oral dosage form in an amount from about 0.5 mg to about 1500 mg;

wherein the oxycodone and/or at least one pharmaceutically acceptable salt thereof is present in the oral dosage form in an amount from 2.5 mg to 800 mg;

wherein said dosage form comprises a sustained release carrier in an amount such that said oral dosage form provides a therapeutic effect for about 12 hours or longer.

39- 46. (cancelled):

47. (previously presented): The method of claim 38, wherein the ratio of oxycodone and/or at least one pharmaceutically acceptable salt thereof to meloxicam and/or at least one pharmaceutically acceptable salt thereof is from about 0.0001:1 to about 1:1.

48. (previously presented): The method of claim 38, wherein the oxycodone is present in the pharmaceutically acceptable salt form.

49-52. (cancelled)

53. (previously presented): The method of claim 38, wherein said sustained release carrier is selected from the group consisting of an alkylcellulose; a hydroxyalkylcellulose; an acrylic polymer; a fatty acid; a fatty alcohol; a glyceryl ester of fatty acids; a mineral oil or wax; a vegetable oil or wax; a polyalkylene glycol; shellac; zein; and mixtures of any of the foregoing.

54. (currently amended): The method of claim 38, wherein said pain is cancer pain, post-surgical pain, low back or ~~and~~ neck pain, dysmenorrheal, headache, toothache, pain from sprains and strains, myositis, neuralgia, synovitis, arthritis, degenerative joint diseases, gout, ~~and~~ ankylosing spondylitis, bursitis, burns, injuries, influenza or other viral infections, ~~and~~ or common cold.

55. (previously presented): A method of effectively treating moderate to severe pain in humans comprising

orally administering to a human patient an oral dosage form comprising two analgesic compounds and/or pharmaceutically acceptable salts thereof consisting of

(i) meloxicam and/or at least one pharmaceutically acceptable salt thereof; and

(ii) oxycodone and/or at least one pharmaceutically acceptable salt thereof;

wherein said dosage form comprises (a) said meloxicam in immediate release form and (b) said oxycodone in sustained release form, said oral dosage form further comprising a sustained release carrier in an amount such that said oral dosage form provides a therapeutic effect of said oxycodone for at least 12 hours or longer.

56. (previously presented): The method of claim 55, wherein said sustained release carrier is selected from the group consisting of an alkylcellulose; a hydroxyalkylcellulose; an acrylic polymer; a fatty acid; a fatty alcohol; a gylceryl ester of fatty acids; a mineral oil or wax; a vegetable oil or wax; a polyalkylene glycol; shellac; zein; and mixtures of any of the foregoing.

57. (currently amended): The method of claim 55, wherein said pain is cancer pain, post-surgical pain, low back ~~and~~ or neck pain, dysmenorrheal, headache, toothache, pain from sprains and strains, myositis, neuralgia, synovitis, arthritis, degenerative joint diseases, gout, ~~and~~ ankylosing spondylitis, bursitis, burns, injuries, influenza or other viral infections, ~~and~~ or common cold.

58. (previously presented): The method of claim 55, wherein said dosage form comprises particles, wherein said particles have diameter from about 0.1 mm to about 2.5 mm.

59. (previously presented): The method of claim 58, wherein said particles have diameter from about 0.5 mm to about 2 mm.

60. (previously presented): The method of claim 55, wherein the meloxicam is coated onto a tablet comprising oxycodone in sustained release form.

61. (previously presented) The method of claim 55, wherein said sustained release carrier being (i) a sustained release coating; or (ii) incorporated into a matrix with said oxycodone.

62. (previously presented): The method of claim 55, wherein said oral dosage form provides a therapeutic effect of said oxycodone for about 24 hours.

63. (previously presented): The method of claim 38, wherein the oral dosage form is administered twice-a-day.

64. (previously presented): The method of claim 55, wherein the oral dosage form is administered twice-a-day.